Metastatic CRC OS | mRNA Vaccine Response | RCTs in Precision OncologyMarch 30, 2021 | Oncology Internal Medicine Anlotinib Prolongs OS in RAS, KRAS, BRAF-Wildtype Metastatic CRC According to research presented at the virtual ASCO GI Cancers Symposium from the phase 3 ALTER0703 trial, anlotinib was beneficial in Chinese patients with refractory metastatic colorectal cancer (CRC), with particular overall survival (OS) improvement – the primary endpoint – among patients with RAS/KRAS/BRAF-wildtype. Read full article Hematology Cancer Patients Respond Poorly to First COVID mRNA Vax Dose The data, concluded in a report posted to the preprint server medRxiv, support prioritization of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine, as barely one-quarter of patients with cancer obtained protection (28% immune efficacy rate, including 13% in patients with blood cancers) against COVID-19 after one dose of the Pfizer/BioNTech vaccine. Read full article Hematology Evolution of the Randomized Clinical Trial in the Era of Precision Oncology In this Original Investigation from JAMA Oncology, the authors seek to discover the characteristics that define modern randomized clinical trials (RCTs) in oncology and whether they differ from characteristics of RCTs from the preceding decades, as concerns have emerged regarding the use of putative surrogate end points, such as progression-free survival (PFS) and marginal effect sizes. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS